Company profile: Pivot Bio
1.1 - Company Overview
Company description
- Provider of microbial nitrogen solutions for crop nutrition, including Pivot Bio PROVEN® 40 for corn and RETURN® for wheat and small grains, delivering steady nitrogen at the root on-seed or in-furrow; the N-OVATOR™ program that rewards reduced synthetic fertilizer use; and NLIGHTEN®, an in-furrow tank system for precise microbial nitrogen delivery with equipment reimbursement.
Products and services
- Pivot Bio PROVEN® 40: Field-scale microbial nitrogen product for corn that delivers steady nitrogen at the plant root through critical growth stages, deployable on-seed or via in-furrow application
- NLIGHTEN®: Precision-calibrated in-furrow tank system that delivers precise amounts of microbial nitrogen at the root on every acre, with an equipment reimbursement program for PROVEN® 40 or RETURN® users
- Pivot Bio RETURN®: Agronomic-grade microbial nitrogen product for wheat and small grains that delivers consistent nitrogen to the plant root, compatible with on-seed treatment or in-furrow placement
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Pivot Bio
Variant Bio
HQ: United States
Website
- Description: Provider of genomics-driven drug discovery, using whole-genome sequencing and custom algorithms to identify novel, population-specific variants and disease-relevant targets. Offers research partnerships, benefit-sharing programs, and an Affordable Medicines Pledge, plus the Variant Bio Standley Fellowship for genomic data analysis and partnerships with populations with specific health-related traits.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Variant Bio company profile →
Ginkgo Bioworks
HQ: United States
Website
- Description: Provider of biological engineering products and custom microbes, designing, engineering, developing, testing, and licensing organisms. Discovers molecules for flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals, and provides probiotic bacteria.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ginkgo Bioworks company profile →
Decode Genetics
HQ: Iceland
Website
- Description: Provider of biopharmaceutical diagnostic tests for gene variant detection, using population studies to identify human genes linked to common diseases and applying findings to guide candidate drug development; has discovered key genetic risk factors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Decode Genetics company profile →
Clear Labs
HQ: United States
Website
- Description: Provider of biotechnology solutions that integrate a genomics system to simplify diagnostics for the clinical and application sectors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clear Labs company profile →
Lynx Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology diagnostic and therapeutic solutions, including Lynxgen Therapeutics LongSAGE mRNA for mRNA sequence analysis to support precision treatment and diagnostics; globally distributed ELISA kits for detecting biomarkers such as chemokines and COVID-19; and exosome-based methods for diagnostics and therapy addressing antibiotic resistance in Mycoplasma pneumoniae.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lynx Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Pivot Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Pivot Bio
2.2 - Growth funds investing in similar companies to Pivot Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Pivot Bio
4.2 - Public trading comparable groups for Pivot Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →